Pilocarpine

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Pilocarpine
    1. Pharmacist Assessment Report
    2. Pilocarpine: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Safety Considerations
    8. Disclaimer

Pharmacist Assessment Report

Pilocarpine: Known uses and market status in Australia

Summary

The TxGNN deep-learning model produced candidates for Pilocarpine with a score of 0.99 or higher. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication. The one known use is primary hereditary glaucoma, which is supported by a licence in another country.

Quick overview

Item Content
New predicted indications None (all traceable model candidates are known uses)
Known uses among model candidates 1
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication Source
primary hereditary glaucoma licence in another country (approved indication: glaucoma)
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence Product Dosage form Status
14355M Isopto Carpine Eye drops containing pilocarpine hydroch Valid

Safety Considerations

Contraindications flagged in the knowledge graph (these come from graph relationships, not from product label text):

  • Eye: angle-closure (closed-angle) glaucoma, uveitis, iritis, iridocyclitis, keratitis, keratoconjunctivitis, retinal detachment
  • Lung: asthma, chronic obstructive pulmonary disease (including severe early-onset), other bronchial disease
  • Kidney and urinary: nephrolithiasis (including SLC26A1-related susceptibility), acute urate nephropathy
  • Liver and biliary: liver failure, cholelithiasis, cholecystolithiasis, choledocholithiasis, cholecystitis, biliary tract disease, obstructive jaundice

Drug Interactions: The interaction search returned 100 records. The main ones are:

  • Moderate (additive or opposing anticholinergic effects): hyoscyamine, atropine (including ophthalmic), glycopyrronium (including topical), clidinium, dicyclomine, mepenzolate, methscopolamine, propantheline, scopolamine (including ophthalmic), trospium
  • Severity unknown: pantoprazole, omeprazole, lansoprazole, clotrimazole, morphine, metformin, epinephrine

Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.